Key Takeaways CRISPR Therapeutics and Sirius start a phase II study of SRSD107 in thromboembolic disorders.SRSD107 targets Factor XI to prevent venous thromboembolism in knee arthroplasty patients.The collaboration expands CRISPR Therapeutics' pipeline into RNA therapeutics beyond gene therapies.CRISPR Therapeutics (CRSP) , along with privately held biotech, Sirius Therapeutics, announced the dosing of the first patient in a phase II study evaluating SRSD107, a next-generation, long-acting siRNA therapy for ...

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI ...

公司评级与目标价 - 摩根大通首次给予CRISPR Therapeutics增持评级 目标价设定为70美元 [1] - 公司凭借管线潜力在基因编辑领域占据独特优势 [1] 技术平台与管线进展 - 公司通过自身免疫CAR-T候选药物CTX112提供更快市场进入路径 [1] - 基于ANGPTL3和Lp(a)候选药物的体内心血管技术构成下一增长曲线 [1][1] - 与福泰制药合作销售Casgevy体内基因编辑疗法 [1] 战略定位与行业优势 - 公司在自身免疫细胞疗法与体内心血管赛道间取得战略平衡 [1] - 公司储备充足资源可规避部分基因编辑同行面临的困境 [1] - 制药行业对心血管靶点保持高度关注背景 [1][1] 发展前景 - 公司投资组合接近多个关键发展拐点 [1] - 体内心血管技术提供极具吸引力的增长机会 [1][1]

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene editing space thanks to its pipeline potential. The Swiss biotech, which markets ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My last update on CRISPR Therapeutics AG (NASDAQ: CRSP ) for Seeking Alpha was posted on July 23rd. It was full of praise for theThe group is for both novice and experienced biotech investors. It provides catalysts ...

新闻订阅服务 - 提供针对生物技术、制药和医疗保健行业股票的每周新闻订阅服务 重点关注行业趋势和估值驱动因素 [1] - 服务内容涵盖催化剂提示 买卖评级 产品销售预测 综合财务报表 贴现现金流分析和分市场分析 [1] - 分析师团队具备超过5年行业研究经验 已完成超过1000家公司的详细研究报告 [1] 分析师持仓披露 - 分析师通过股票、期权或其他衍生工具持有CRISPR Therapeutics AG（CRSP）的多头头寸 [2] 内容免责声明 - 分析内容代表作者个人观点 未获得除Seeking Alpha以外任何形式的补偿 [2] - 分析机构与提及公司不存在业务关系 [2] - 分析作者包含专业投资者和个体投资者 可能未获得任何机构或监管机构的许可或认证 [3]

核心观点 - 公司被分析师视为当前最佳新兴科技股之一 拥有买入评级和78美元目标价[1] - 公司基于CRISPR/Cas9基因编辑平台开发变革性疗法 管线涵盖血液疾病、癌症和罕见遗传病[2][6] - 分析师看好公司销售增长势头和管线扩张 季度销售额环比增长114% 并新增峰值收入40亿美元的产品预测[3][4] 分析师评级与目标价 - 美国银行证券分析师Alec Stranahan重申买入评级 目标价78美元[1] - H C Wainwright分析师Mitchell Kapoor重申买入评级 将目标价从65美元上调至80美元[3] 技术平台与研发管线 - CRISPR/Cas9基因编辑平台能够精确修改DNA序列并直接纠正缺陷基因[2] - 研发管线覆盖血红蛋白病、肿瘤学、再生医学和罕见遗传疾病领域[2][6] 商业化进展与财务表现 - CASGEVY在2025年第二季度销售额实现114%的环比增长[3] - 已授权治疗中心扩大至75个 加速患者采用率[4] - 公司现金储备充足 可维持运营至2027年[4] 产品管线价值评估 - 新增CTX310产品预测 峰值收入潜力达40亿美元[4] - 结合分析师信心、销售增长和强大管线 公司正从研发承诺转向商业化交付阶段[5]

In this article, we will examine the Best Emerging Technology Stocks to Buy Right Now.While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence began rewriting them. Every generation experiences a turning point where technology doesn’t just improve how we live, but also reshapes the foundation of society. Today, we are at such a point.Emerging technologies, including biotechnology, artificial intelligence, quantum computing, and autonomous sys ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $176.57 per unit.With IYY trading at a recent price near $160.66 per unit, that mean ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about CRISPR Therapeutics AG (CRSP) .CRISPR Therapeutics currently has an averag ...